Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CureVac N.V. CVAC

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.


Recent & Breaking News (NDAQ:CVAC)

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

Accesswire 10 days ago

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

Accesswire November 11, 2022

CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

Accesswire November 10, 2022

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Accesswire August 18, 2022

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Accesswire August 18, 2022

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Accesswire July 5, 2022

CureVac Announces Voting Results of General Meeting

Accesswire June 22, 2022

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

Accesswire June 8, 2022

CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen

Accesswire June 8, 2022

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

Accesswire May 25, 2022

Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update

Accesswire May 25, 2022

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

Accesswire April 28, 2022

CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

Accesswire April 22, 2022

CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

Accesswire April 21, 2022

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

Accesswire April 11, 2022

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

Accesswire March 30, 2022

CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)

Accesswire March 1, 2022

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Accesswire February 10, 2022

CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

Accesswire January 17, 2022

dievini and the Federal Republic of Germany Amend Shareholders' Agreement Regarding Investments in CureVac N.V.

Accesswire January 13, 2022